PAR-22-174: Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
Closed
This grant is closed. A newer notice from the same program is open now: Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional) (PAR-25-103). Status: Due dates in the notice, expires October 25, 2027. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $600,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 4, 2024.
From the official notice on Grants.gov, last changed November 5, 2024. Checked November 7, 2026.
- Award ceiling$600,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU34
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$289,218
- Typical project length3 years
- U34, Planning Cooperative Agreement. Planning a clinical trial, with substantial NIH involvement. Other open U34 notices.
Projects funded under PAR-22-174 were run by National Cancer Institute (NCI, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-22-174 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-103 | November 5, 2024 | Due dates in the notice, expires October 25, 2027 | Open |
Key dates
| Posted | June 23, 2022 |
|---|---|
| Deadline | November 4, 2024 |
| Archived by Grants.gov | December 4, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $289,218; it allows up to $600,000 per award.
- Most of the program's money (64% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
Funded under PAR-22-174 so far
NIH funded 3 projects under PAR-22-174 in fiscal 2023 to 2026, at 2 institutions. The median yearly award was $289,218.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Distance-based Exercise to preserve Function and prevENt Disability (DEFEND) | Dana-Farber Cancer Inst | 2026 | $336,614 |
| Collaborative Oncology: Preparing for a Multisite Trial to Facilitate Communication between Radiation Oncologists and Radiologists in Cancer Treatment Planning and Surveillance | Wake Forest University Health Sciences | 2026 | $319,106 |
| Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers | Wake Forest University Health Sciences | 2025 | $283,650 |
Who has won Cancer Control grants before
From fiscal 2021 to 2025, Cancer Control (93.399) awarded $814 million across 113 grant awards, an average of $7.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Ecog-Acrin Medical Research Foundation, Inc. | Pennsylvania | 1 | $87.9 million |
| NRG Oncology Foundation Inc | Pennsylvania | 1 | $54.3 million |
| Alliance NCTN Foundation | Illinois | 1 | $50.2 million |
| Oregon Health & Science University | Oregon | 2 | $34.4 million |
| University of Rochester | New York | 1 | $29.8 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-25-103, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-22-174 still open?
No. It closed on November 4, 2024. A newer notice is open: PAR-25-103, due dates in the notice, expires October 25, 2027.
Who can apply for Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)?
Closed November 4, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $600,000 each.
Who has been funded under PAR-22-174?
NIH RePORTER lists 3 projects funded under PAR-22-174 in fiscal 2023 to 2026, at 2 institutions. The most were at Wake Forest University Health Sciences, Dana-Farber Cancer Inst.
Who has won Cancer Control grants before?
The largest recipients over five fiscal years were Ecog-Acrin Medical Research Foundation, Inc., NRG Oncology Foundation Inc, Alliance NCTN Foundation. The program made 113 awards worth $814 million in that time.
Similar open grants
- Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)